PL1678297T3 - Sposób produkcji gamma-karboksylowanych białek - Google Patents

Sposób produkcji gamma-karboksylowanych białek

Info

Publication number
PL1678297T3
PL1678297T3 PL04775534T PL04775534T PL1678297T3 PL 1678297 T3 PL1678297 T3 PL 1678297T3 PL 04775534 T PL04775534 T PL 04775534T PL 04775534 T PL04775534 T PL 04775534T PL 1678297 T3 PL1678297 T3 PL 1678297T3
Authority
PL
Poland
Prior art keywords
producing gamma
carboxylated proteins
carboxylated
proteins
gamma
Prior art date
Application number
PL04775534T
Other languages
English (en)
Inventor
Christel Fenge
Ann Lövgren
Anders Thelin
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29559260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1678297(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of PL1678297T3 publication Critical patent/PL1678297T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
PL04775534T 2003-10-14 2004-10-12 Sposób produkcji gamma-karboksylowanych białek PL1678297T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0324044.7A GB0324044D0 (en) 2003-10-14 2003-10-14 Protein
PCT/SE2004/001453 WO2005038019A1 (en) 2003-10-14 2004-10-12 Method for producing gamma-carboxylated proteins
EP04775534A EP1678297B1 (en) 2003-10-14 2004-10-12 Method for producing gamma-carboxylated proteins

Publications (1)

Publication Number Publication Date
PL1678297T3 true PL1678297T3 (pl) 2011-11-30

Family

ID=29559260

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04775534T PL1678297T3 (pl) 2003-10-14 2004-10-12 Sposób produkcji gamma-karboksylowanych białek

Country Status (29)

Country Link
US (2) US7842477B2 (pl)
EP (2) EP2292748B1 (pl)
JP (1) JP4658946B2 (pl)
KR (1) KR101201020B1 (pl)
CN (2) CN102443548B (pl)
AR (1) AR046180A1 (pl)
AT (1) ATE491789T1 (pl)
AU (2) AU2004281350B2 (pl)
BR (1) BRPI0415277A (pl)
CA (1) CA2541764C (pl)
CO (1) CO5690657A2 (pl)
DE (1) DE602004030603D1 (pl)
DK (1) DK1678297T3 (pl)
ES (2) ES2532470T3 (pl)
GB (1) GB0324044D0 (pl)
HK (1) HK1155475A1 (pl)
IL (2) IL174633A (pl)
IS (1) IS8447A (pl)
MX (1) MXPA06004060A (pl)
MY (1) MY141859A (pl)
NO (1) NO339740B1 (pl)
NZ (2) NZ546584A (pl)
PL (1) PL1678297T3 (pl)
PT (1) PT1678297E (pl)
RU (2) RU2372401C2 (pl)
TW (1) TWI355419B (pl)
UY (1) UY28558A1 (pl)
WO (1) WO2005038019A1 (pl)
ZA (1) ZA200603038B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
CN101198696B (zh) * 2005-04-13 2014-02-26 阿斯利康(瑞典)有限公司 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞
CA2624072A1 (en) * 2005-09-30 2007-04-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing recombinant human thrombin by cultured cell
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
PT1969127E (pt) * 2005-12-21 2014-09-23 Univ North Carolina Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes
EP1996186A4 (en) * 2006-03-06 2009-07-22 Humagene Inc PROCESS FOR THE PREPARATION OF RECOMBINANT HUMAN THROMBIN AND FIBRINOGEN
EP2139499A4 (en) * 2007-04-26 2010-05-05 Inspiration Biopharmaceuticals RECOMBINANT VITAMIN K-DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHOD FOR THE PRODUCTION THEREOF
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
CN103221061A (zh) * 2010-10-06 2013-07-24 米迪缪尼有限公司 用于治疗止血障碍的因子ii以及纤维蛋白原
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
AU2012304763A1 (en) 2011-09-06 2014-03-06 Medimmune Llc Methods for processing coagulation factors
RU2500816C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАК380, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1E6 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ РЕКОМБИНАНТНОГО ФАКТОРА IХ
JP5830486B2 (ja) 2013-03-29 2015-12-09 シスメックス株式会社 組換えバキュロウイルスおよびその利用
CA2934412C (en) * 2013-12-20 2024-02-20 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
CN109207462B (zh) * 2018-08-01 2021-05-11 深圳市新产业生物医学工程股份有限公司 异常凝血酶原及其制备方法和包含其的检测剂、试剂盒及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043857A1 (de) 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
US4599308A (en) * 1981-10-06 1986-07-08 Hamer Dean H Protein from SV40 recombinants
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JPH01502080A (ja) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
US6224864B1 (en) 1986-12-03 2001-05-01 Pharmacia & Upjohn Company Antibiotic 10381A, and process for the preparation of anitbiotics 10381B
WO1989012685A1 (en) 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5118614A (en) 1988-01-18 1992-06-02 Tessek Sdruzeni Praha Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
EP0540650A1 (en) 1990-07-23 1993-05-12 Zymogenetics, Inc. Gamma-carboxylase and methods of use
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
DE59712322D1 (de) 1996-03-20 2005-06-30 Baxter Ag Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
JP2001522230A (ja) * 1997-02-14 2001-11-13 アメリカン・レツド・クロス トランスジェニック動物乳房組織における活性ヒト第▲ｉｘ▼因子の発現
AU2015799A (en) 1997-12-24 1999-07-19 Immunex Corporation V201 dna and polypeptides
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
AU6366100A (en) 1999-07-23 2001-02-13 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
AU2001268373A1 (en) * 2000-06-13 2001-12-24 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
DE60137950D1 (de) 2000-10-02 2009-04-23 Novo Nordisk Healthcare Ag Verfahren zur herstellung vitamin-k-abhängiger proteine
CA2452768C (en) 2001-07-06 2011-06-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for preparing human thrombin by genetic engineering technique
CN1551918B (zh) 2001-07-06 2011-04-20 财团法人化学及血清疗法研究所 基因重组伊卡因及其制备方法
CA2452395C (en) 2001-07-10 2012-04-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Pharmaceutically stable hemostatic compositions
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
EP2189523B1 (en) 2003-10-14 2012-01-04 Baxter International Inc. Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
ATE465245T1 (de) 2003-10-24 2010-05-15 Chemo Sero Therapeut Res Inst Neue rekombinante tierzellen mit hoher proteinproduktion, verfahren zur konstruktion davon sowie verfahren zur massenproduktion von protein unter verwendung davon
WO2006067116A1 (en) 2004-12-21 2006-06-29 Novo Nordisk Health Care Ag Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
CN101198696B (zh) 2005-04-13 2014-02-26 阿斯利康(瑞典)有限公司 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞
WO2007065173A2 (en) 2005-12-02 2007-06-07 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
PT1969127E (pt) 2005-12-21 2014-09-23 Univ North Carolina Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin

Also Published As

Publication number Publication date
EP2292748B1 (en) 2014-12-17
KR20060123152A (ko) 2006-12-01
EP1678297B1 (en) 2010-12-15
NO339740B1 (no) 2017-01-30
CN102443548B (zh) 2014-03-12
DE602004030603D1 (de) 2011-01-27
ATE491789T1 (de) 2011-01-15
US20050164367A1 (en) 2005-07-28
BRPI0415277A (pt) 2006-12-19
EP2292748A1 (en) 2011-03-09
AU2008205445A1 (en) 2008-09-04
IL174633A0 (en) 2006-08-20
IL174633A (en) 2013-06-27
US8697440B2 (en) 2014-04-15
CA2541764A1 (en) 2005-04-28
RU2006110147A (ru) 2007-11-20
ES2532470T3 (es) 2015-03-27
CN102443548A (zh) 2012-05-09
TW200523365A (en) 2005-07-16
RU2372401C2 (ru) 2009-11-10
UY28558A1 (es) 2005-05-31
AR046180A1 (es) 2005-11-30
CO5690657A2 (es) 2006-10-31
GB0324044D0 (en) 2003-11-19
NZ546584A (en) 2009-08-28
US20110092429A1 (en) 2011-04-21
IS8447A (is) 2006-05-10
AU2004281350A1 (en) 2005-04-28
NO20061470L (no) 2006-05-12
CN1867669B (zh) 2011-10-19
KR101201020B1 (ko) 2012-11-14
CN1867669A (zh) 2006-11-22
ZA200603038B (en) 2007-09-26
MY141859A (en) 2010-07-16
NZ578306A (en) 2011-02-25
IL226313A0 (en) 2013-06-27
US7842477B2 (en) 2010-11-30
WO2005038019A1 (en) 2005-04-28
DK1678297T3 (da) 2011-03-14
JP4658946B2 (ja) 2011-03-23
ES2357603T3 (es) 2011-04-28
RU2009123931A (ru) 2010-12-27
MXPA06004060A (es) 2006-06-28
EP1678297A1 (en) 2006-07-12
CA2541764C (en) 2015-03-31
TWI355419B (en) 2012-01-01
AU2004281350B2 (en) 2008-05-15
JP2007508820A (ja) 2007-04-12
HK1155475A1 (en) 2012-05-18
PT1678297E (pt) 2011-03-15

Similar Documents

Publication Publication Date Title
HK1155475A1 (en) Method for producing gamma-carboxylated proteins
EP1514928A4 (en) METHOD FOR CONSTRUCTING ANTIBODIES
PL1611184T3 (pl) Sposób wytwarzania poliamidów
EP1748077A4 (en) PROCESS FOR PROTEIN PRODUCTION
IL172234A0 (en) Method for preparing fused oxazinones
PL1835816T3 (pl) Sposób wytwarzania hydrolizatów białkowych
EP1662555A4 (en) PROCESS FOR PRODUCING SOI PLATEBOARD
AU2003283174A8 (en) Method for protein production
PL1697390T3 (pl) Sposób wytwarzania organoacylofosforynów
GB2387599B (en) Methods for producing antibodies
TWI348457B (en) Method for producing 帢-alumina particulate
EP1688422A4 (en) PROCESS FOR PREPARING AN ORGANOSILANE
EP1604957A4 (en) PROCESS FOR PRODUCING GLASS MATERIAL
EP1612213A4 (en) PROCESS FOR PREPARING 2-DESOXY-2-FLUORURIDINE
HK1082000A1 (en) Method for producing cephalexin
EP1632478A4 (en) PROCESS FOR PRODUCING PURIFIED 2-CYANOACRYLATE
EP1698703A4 (en) PROCESS FOR DIPEPTIDE PRODUCTION
EP1662550A4 (en) METHOD FOR PRODUCING AN SOI WATER
EP1693386A4 (en) METHOD FOR THE PRODUCTION OF ANTIBODIES
PL1651784T3 (pl) Sposób wytwarzania koncentratów
HK1133870A1 (en) Method for producing 4-pentafluoride-sulfanyl-benzoylguanidines
EP1556396A4 (en) METHOD OF PRODUCING 2-DESOXY-L-RIBOSE
EP1658375A4 (en) PROCESS FOR THE PREPARATION OF DIPEPTIDES
EP1666474A4 (en) PROCESS FOR PRODUCTION OF PROPYLENEOXIDE
EP1676853A4 (en) ALPHA-1-PHOSPHORYL-2-DESOXY-2-FLUOROARABINOSIDE AND PROCESS FOR PRODUCING 2'-DESOXY-2'-FLUORO-BETA-D-ARABINONUCLEOSIDE